A randomised trial of carboplatin versus carboplatin and thalidomide in ovarian cancer, with evaluation of potential surrogate markers of angiogenesis

S. Muthuramalingam(Churchill Hospital), Trivadi S. Ganesan(Churchill Hospital), Timothy Perren(University of Leeds), Chengcheng Han(Asia Pacific Center for Theoretical Physics), S. Wilner, Jeremy Braybrooke(University Hospitals Bristol NHS Foundation Trust), A. Jenkins(Churchill Hospital), Andrew D. Blann(Birmingham City Hospital), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)

Journal of Clinical Oncology

July 15, 2004

10.1200/jco.2004.22.14_suppl.5024

Cited by 1

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

|New England Journal of Medicine|2010|4.5k

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

|The Lancet|2022|664

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

|The Lancet Oncology|2013|605

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

|The Lancet Oncology|2014|374

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

|The Lancet Oncology|2020|351